A few other states are planning or considering obesity drug restrictions in state fiscal year 2026 or 2027, and state interest in expanding coverage of obesity drugs is also waning according to this years survey, with states continuing to report cost as the key factor contributing to obesity drug coverage decisions
Frequently Asked Questions About Retatrutide vs Mounjaro What is better, Retatrutide or Mounjaro
However, Asia-Pacific emerges as the fastest-growing region, fueled by rapidly increasing diabetes prevalence, expanding middle-class populations, and improving healthcare access in countries like China and India
The fix: Prepare before week 6
Were not about a quick-fix crash diet that doesnt educate you on how to lead a healthier lifestyle
Cost and tolerability are common reasons for patients to discontinue GLP-1 agonists or not even be able to start them in the first place, Tan says